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This chapter is written to make the fast-paced, expand-
ing field of the genetics of autism accessible to those
practitioners who help children with autism. New genetic
knowledge and technology have quickly developed over
the past 30 years, particularly within the past decade, and
have made many optimistic about our ability to explain
autism. Among these advances include the sequencing of
the human genome (Lander et al., 2001) and the identifi-
cation of common genetic variants via the HapMap project
(International HapMap Consortium, 2005), and the develop-
ment of cost-efficient genotyping and analysis technologies
(Losh, Sullivan, Trembath, & Piven, 2008). Improvement in
technology has led to improved visualization of chromoso-
mal abnormality down to the molecular level. The four most
common syndromes associated with autism include frag-
ile X syndrome, tuberous sclerosis, 15q duplications, and
untreated phenylketonuria (PKU; Costa e Silva, 2008). FXS
and 15q duplications are discussed within the context of cyto-
genetics. TSC is illustrated within the description of linkage
analysis.
As recently reviewed (Li & Andersson, 2009), the first
inkling of chromosomal anomaly causing clinical pathology
occurred in 1959 when an extra copy of chromosome 21
was associated with the Down syndrome phenotype. Shortly
thereafter, chromosomal abnormality was recognized for
Patau’s syndrome (trisomy 13) and Edward’s syndrome (tri-
somy 18). The chromosomal banding technique developed
in 1970 led to the identification of many structural chromo-
somal abnormalities associated with clinical conditions. The
discovery that genes located close to each other on a chro-
mosome are often inherited together led to linkage analysis
in the 1970s and 1980s. Linkage techniques related chro-
mosomal abnormalities with known genetic anomalies using
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an affected sibling–pair design in multiplex (having more
than one affected member) families. This led to the identi-
fication of chromosomal abnormalities in such conditions as
neurofibromatosis, tuberous sclerosis, and dyslexia (Smith,
2007). Improving technology in the 1990s enabled the detec-
tion of small genomic alterations of 50–100 kb and the direct
visualization of these alterations in uncultured cells via fluo-
rescent in situ hybridization (FISH). This technique ushered
in the field of molecular genetics (Li & Andersson, 2009)
and allowed the identification of chromosomal microdele-
tions and duplications in areas of the chromosome where
there is already high suspicion that abnormality would exist.
FISH enables prenatal and cancer genetics screening and has
led to the identification of genetic aberrations associated with
Angelman’s and Prader Willi syndromes.
In the past decade, microarray cytogenetics has per-
mitted the study of the entire genome on a single chip
with resolution as fine as a few hundred base pairs (Li &
Andersson, 2009). Such microarray technology represents a
union between molecular genetics and classical cytogenetics.
Two types of microarray technology are used clinically: com-
parative genomic hybridization (CGH) and single-nucleotide
polymorphism (SNP) analysis. CGH directly measures copy
number differences between a patient’s DNA and a nor-
mal reference DNA spanning known genes, chromosomal
regions, or across the entire genome. SNP analysis, on the
other hand, provides identification of a single point mutation
via sequencing the gene in areas of suspected abnormality,
previously identified via CGH or FISH. Another offshoot
of microarray technology is submicroscopic chromosome
copy number variation (CNV) analysis, in which deletions
or duplications involving > 1-kb DNA have been detected
in patients with mental retardation, autism, and multiple
congenital anomalies.
There are several recent, detailed reviews of the genetics
of autism (Abrahams & Geschwind, 2008; Li & Andersson,
2009; Losh et al., 2008; O’Roak & State, 2008) and this
chapter summarizes those reviews. The reader is encouraged
to first review the overview of gene expression (Box 6.1) and
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essential nomenclature used in genetics (Box 6.2). In addi-
tion, one must understand basic concepts pertinent to brain
development (Box 6.3) and to the neurobiology of autism
(Box 6.4) in order to understand its genetics. For exam-
ple, there is a compelling rationale that genetically directed
mechanisms that regulate the assembly of the brain during
embryogenesis, when gone awry, may cause autism (Costa e
Silva, 2008).
Box 6.1 Overview of DNA Replication and Gene
Expression∗
Genes. A gene is a unit of hereditary material located
in a specific place (locus) on a chromosome. Most
genes carry the instructions for producing a spe-
cific protein. A protein-coding human gene will have
a coding sequence, which contains the information
for protein production. The coding sequence may
be broken up into several sub-sequences, or exons,
which are separated by noncoding DNA sequences,
or introns. The coding sequence is flanked by
a promoter and (usually) a 5′-untranslated region
(5′-UTR) that occur immediately before the cod-
ing sequence and by a 3′-UTR and a terminator
that occur immediately after the coding sequence.
Promoters, terminators, UTRs, and introns can reg-
ulate the activity of a given gene. At a molecular
level, chromosomes are composed of long chains of
deoxyribonucleic acid (DNA) upon which genes are
linearly arranged. The DNA exists in a double helix
and the helical strands are usually wrapped around
histone proteins. In addition to DNA and histones,
chromosomes contain scaffolding proteins that pro-
vide structural support and may also participate in
gene regulation. DNA is a molecule composed of
a chain of four different types of nucleotides. It is
the sequence of these nucleotides that is the genetic
information that organisms inherit. DNA is double
stranded with nucleotides on each strand comple-
mentary to each other. Each strand acts as a template
for creating a new partner strand. This is the physical
method for making copies of genes that are inher-
ited. Both individual DNA nucleotides and DNA-
associated proteins can be chemically modified to
produce epigenetic variation that may be in response
to environmental conditions and might or might not
be inherited in any individual case. Epigenetic vari-
ation can significantly alter the expression level of a
gene without changing its basic genetic code.
DNA replication. During DNA replication, a DNA
strand is produced from component nucleotides
using its partner strand as a template. This is done
by DNA polymerases that “proofread” to ensure
accuracy and repair when necessary. Despite these
safeguards, errors called mutations can occur during
the polymerization of this second strand. A muta-
tion is any nucleotide sequence in a DNA molecule
that does not match its original DNA molecule from
which it is copied. Radiation, such as ultraviolet
rays and X-rays, viruses, and errors that occur dur-
ing meiosis or during DNA replication can cause
errors in DNA molecules. These mutations can have
an impact on the phenotype of an organism, espe-
cially when they occur within the protein-coding
sequence of the gene. Kinds of mutations include the
following:
Frameshift Mutation: One or more bases are inserted
or deleted. This can alter the entire amino acid
sequence of a protein or introduce aberrant RNA
splicing.
Deletion. Missing DNA sequences can range from
a single base pair to longer deletions involving
many genes in the chromosome.
Insertion. Additional nucleotides are inserted in the
DNA sequence and can result in a nonfunctional
protein.
Duplication (or gene amplification). Multiple copies of
a complete gene or genes, increasing the dosage of
genes located within chromosomes.
Inversion. DNA sequence of nucleotides is reversed,
either among a few bases within one gene or among
longer DNA sequences containing several genes.
Point mutations. Known as substitutions, this is a
replacement of a single base nucleotide with another
nucleotide.
Missense mutations. A point mutation where a sin-
gle nucleotide is changed to cause substitution of
a different amino acid.
Nonsense mutation. A point mutation that results in
a premature stop codon in the transcribed mRNA
and possibly a nonfunctional protein product.
RNA splicing mutation. A point mutation that
inserts or deletes an intron/exon border neces-
sary for splicing of heterogeneous nuclear RNA
to mRNA.
Silent mutation. A point mutation that does not alter
the amino acid coding for that codon.
Gene expression is the process in which genes express
their functional effect through the production of pro-
teins which are responsible for most functions of
the cell. The DNA sequence of a gene is used to
produce a specific protein through a ribose nucleic
acid (RNA) intermediate. Gene DNA is the map
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which directs the production of the protein, normally
following a one-way pathway:
→ → →
DNA hnRNA mRNA Protein
Transcription Splicing Translation
Gene regulation gives the cell control over struc-
ture and function and is the basis for cellular
differentiation and adaptability of any organism.
Gene regulation is controlled by noncoding DNA
sequences, such as the promoter, terminator, or
introns, and by epigenetic variation, such as differ-
ences in DNA methylation and histone acetylation.
This entire process takes place within the cell in
the vicinity of the nucleus, where DNA is housed
and hnRNA is spliced, and in the cytoplasm, where
ribosomes are located along the rough endoplasmic
reticulum. Some proteins are further processed in
the Golgi apparatus if they are to be exported from
the cell. The correspondence between nucleotide
and amino acid sequence is known as the genetic
code.
RNA transcription. In transcription, DNA is used as a
blueprint for the production of RNA. Transcription
is performed by RNA polymerase which adds one
ribonucleotide to a growing RNA strand, com-
plimentary to the DNA nucleotide being tran-
scribed. This product is heterologous nuclear RNA
(hnRNA).
RNA splicing. In splicing, hnRNA is processed within
the nucleus to remove introns which may function to
partially regulate transcription and join exons, which
code for the actual protein product. The product of
slicing is mRNA.
Translation. Translation is the production of proteins
by decoding the mRNA that was produced by tran-
scription and splicing. The mRNA sequence is the
template that guides the production of a chain of
amino acids that form a protein.
∗Pack (2002)
Box 6.2 Genetic Terms∗∗
Allele. This is an alternate DNA sequence at the same
physical gene locus which may represent different
phenotypes. For example, for ABO blood type, there
are three alleles, I0, IA, and IB. Any individual has
one of six genotypes (AA, AO, BB, BO, AB, and
OO) that produce four phenotypes: “A” (produced
by AA homozygous and AO heterozygous geno-
types), “B” (produced by BB homozygous and BO
heterozygous genotypes), “AB” heterozygotes, and
“O” homozygotes.
Association Study. A test to determine whether a par-
ticular variant (allele) of a marker or a gene occurs
more frequently in those with the disorder than in
those without the disorder. It detects effects in much
smaller regions of the genome than linkage.
Comparative genomic hybridization (CGH). A
microarray technique that directly measures copy
number differences between a patient’s DNA and
a normal reference DNA spanning known genes,
chromosomal regions, or across the entire genome.
Copy number variation (CNV) analysis. This technique
is an offshoot of microarray technology in which 0,
1, or 3 copies, defined as deletions or duplications
involving >1 kb DNA, are detected in patients with
mental retardation, autism, and multiple congenital
anomalies.
Cytogenetics. Study of the structure and function of a
cell as it relates to the chromosomes
Fluorescent in situ hybridization (FISH). This is a
molecular genetic technique which allows direct
visualization of microdeletions and duplications of
50–100 kb of a specific chromosome region in
uncultured cells. FISH has enabled prenatal screens
for chromosomal abnormality and developmental
conditions such as Angelman’s and Prader Willi
syndromes and postnatal screening for cancer. FISH
can only probe specific sequences that are known
and suspected to be associated with known syn-
dromes.
Genome. The full set of hereditary material in an
organism – usually the combined DNA sequences of
all chromosomes. Genome-wide association studies
(GWAS) compare genetic risk factors in the form of
specific genetic markers in cases and controls. These
markers are distributed across the entire genome
rather than limited to specific gene regions such as
in the sib–pair method.
Genotype: A pair of two alleles which can be the
same (homozygous) or different (heterozygous).
Genotype interactions between the two alleles at
a locus can be dominant (where the heterozy-
gote is indistinguishable from one of the homozy-
gotes), recessive (the allele which is under expressed
if mixed with a dominant allele), semi-dominant
(where the heterozygote resembles the homozy-
gote dominant more than it does the homozygote
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recessive but does not have the full homozygote
dominant trait), or co-dominant (when both alleles
contribute equally to a phenotype that is distinct
from either homozygote). In the case of human
blood types, for example, IA and IB are each dom-
inant over I0, while IA and IB have co-dominance
with each other.
Linkage Study. A test to determine where genetic
markers are inherited along with a given disorder.
When genes are located together on a chromosome,
they are often inherited together. Finding a marker
linked to a disorder gives the approximate location
of a risk gene for that disorder. In the sib–pair link-
age study method, siblings with autism are evaluated
to determine whether they share any region of the
genome more frequently than would be expected by
chance.
Mendelian locus. A single gene variant sufficient to
completely explain a phenotypic trait, such as a dis-
order. Examples of pathogenic variations or muta-
tions of single genes include PKU, sickle cell, and
Angelman’s syndrome.
Mendelian transmission. A condition that is inherited
via autosomal dominant, recessive, or sex-linked
transmission.
Microarray technology. Developed within the last
decade, this technique enables examination of the
whole human genome on a single chip with a res-
olution as high as a few hundred base pairs. This
resolution is at least 10-fold greater than the best
prometaphase chromosomal analysis and therefore,
it is the most sensitive for whole genome screen for
deletions and duplications.
Penetrance. The proportion of individuals carrying a
particular variation of a gene that also expresses
an associated trait. For example, if a mutation has
95% penetrance, then 95% of those with the muta-
tion will develop the syndrome, while 5% will
not.
Quantitative trait locus (QTL). A gene variant that
is expressed along a continuous phenotype, whose
extreme end may produce the disorder such as
hypertension, reading disability, or attention-deficit
disorder with hyperactivity (ADHD).
Recessive genetic disorders. A number of genetic dis-
orders are caused when an individual inherits two
recessive alleles for a single gene trait, such as with
cystic fibrosis, PKU, or albinism. Recessive alleles
can be located on the X chromosome so that males
are more affected than females (hemizygous), such
as in fragile X.
Single-nucleotide polymorphism (SNP) analysis. A
microarray technique that identifies a single point
mutation via sequencing the gene in areas of sus-
pected abnormality as identified via CGH or FISH.
This looks at a smaller region with greater detail
than does CGH.
∗∗Solomon, Berg, and Martin (2008)
Box 6.3 Normal Brain Development
During embryologic development, the brain emerges
from the neural tube, an early embryonic structure. The
anterior neural tube expands rapidly due to cell prolif-
eration and eventually gives rise to the brain. Cells stop
dividing and differentiate into neurons and glial cells,
the main cellular components of the brain. The neurons
must migrate to different parts of the developing brain
to self-organize into different brain structures. The
neurons grow connections (axons and dendrites) which
often must span long distances to reach their target
cells. Growth cones are the highly motile filamentous
connections that eventually form more stable synapses
between neurons. Neurons communicate with other
neurons via these synapses. This communication leads
to the establishment of functional neural circuits that
mediate sensory–motor processing and behavior.
Associated with this period of synaptogenesis is a
brief period of “programmed” cell death, a pruning
process in which cells succumb during natural devel-
opment (Mattson & Furukawa, 1998). Migration of
cells from the ventricular zone lining the central canal
of the neural tube to the developing cortex next takes
place followed by a more protracted period of prun-
ing (Volpe, 2001). One mechanism that allows cells to
detach and migrate away from each other appears to be
regulated by a “molecular switch” regulated by catenin
adhesion proteins (DiCicco-Bloom, 2006). Neuroligin,
recently described in autism research, is a cell adhe-
sion molecule found in the postsynaptic membrane.
Also, brain-derived neurotrophic factor (BDNF) is pro-
duced by the brain and regulates several functions
within the developing synapse, including enhancement
of neurotransmitter release.
Activity at the CNS synapses occurs over the life
span and is thought to underlie learning and mem-
ory. The excitatory neurotransmitter glutamate and
its receptors, particularly the N-methyl-D-aspartate
(NMDA) receptor, initiate synaptogenesis through
activation of downstream products. At the CNS
6 The Genetics of Autism 81
synapse, a nerve terminal is separated from the post-
synaptic membrane by a cleft containing specialized
extracellular material. Localized vesicles are at the
active sites and clustered receptors are at the postsy-
naptic membrane with glial cells that encapsulate the
entire synaptic cleft. There is differentiation of the
pre- and postsynaptic membrane following initial con-
tact between two cells. This includes the clustering
of receptors, localized upregulation of protein synthe-
sis at the active sites, and continued neuronal pruning
through synapse elimination. Neurons within the CNS
receive multiple inputs that must be processed and
integrated for successful transfer of information. The
multiple inputs physically represent the plasticity of
the brain.
Box 6.4 Neurobiology of Autism
Macrocephaly has been one of the “most widely repli-
cated biological findings in autism” (McCaffery &
Deutsch, 2005), affecting up to 20% of all children
with autism. Several reports have shown increased
brain volume (macroencephaly/megalencephaly) in
both white and grey matter with results varying as a
function of age. MRI volumetric studies have showed
increased brain volume in younger (total ages 2–21)
subjects compared to older (total ages 5–21) subjects
(Courchesne, Carper, & Akshoomoff, 2003; Sokol &
Edwards-Brown, 2004; Sparks et al., 2002). To explain
the relevance of brain volume enlargement in autism,
it has been proposed that brain “growth without guid-
ance” occurs in young autistic children (Courchesne
et al., 2001) with premature expansion and over-
growth of neural elements and dendritic connections.
Indeed, brain enlargement appears to develop postna-
tally, arising before or during the early recognition of
autistic behaviors – between 18 months and 3 years
(Courchesne et al., 2003).
Proposed mechanisms underlying brain enlarge-
ment include overproduction of synapses, failure of
synaptic pruning, excessive neurogenesis, gliogene-
sis, or reduction in cell death (McCaffery & Deutsch,
2005). The mechanisms underlying the tremendous
growth of the typically developing embryonic brain,
compared to the relatively more limited postnatal and
adult brain growth, have been implicated in the brain
enlargement seen in autism. This leads to the proposal
that overstimulation of nuclear receptor-mediated gene
transcription may increase neural progenitor cells that
generate marked increases in cortical surface area
(McCaffery & Deutsch, 2005). Therefore, the num-
ber of neurons in the young cortex is a function of
the number of proliferative cells present at the onset
of neurogenesis. Tumor suppressor genes which con-
trol brain growth and migration, when defective, could
contribute to macrocephaly of failure in synaptic prun-
ing. This explains the great interest in tumor suppressor
genes such as PTEN as candidate genes for autism.
Recently, neuronal cell adhesion has been proposed
as another mechanism involved in brain overgrowth
in autism. Cell adhesion suppresses brain growth,
while abnormalities in adhesion promote growth or
contribute to aberrant growth. It is believed that hetero-
geneous causes of autism may be associated with alter-
ations in adhesion molecules of the synapse or cyto-
plasmic molecules associated with synaptic receptors.
Indeed, recent genetic evidence has found associations
between autism susceptibility and other neuronal cell
adhesion molecules, such as NLGN1 and ASTN2 and
specific cadherins.
There is an emerging theory, as recently reviewed in
Geschwind (2009), that short-range brain connections
may be overgrown and longer range brain connections
between different brain lobules are reduced in autism.
In autism, there has been a noted reduction in the size
of the corpus callosum which connects the two cere-
bral hemispheres and reduced connectivity between
the frontal and temporal lobes of the brain, loca-
tions responsible for language and social judgment.
The preservation of normal short-range connections
could explain some of the preserved processing func-
tions such as visual perception or attention to detail
experienced by many with autism (Geschwind, 2009).
Indirect Evidence of Heritability
Three lines of research indirectly attest to the heritability
of autism: twin studies, family studies, and the fact that
autism affects more boys than girls. In general, hereditabil-
ity appears to be greater when a broader definition of autism
(including individuals with cognitive deficits and/or social
impairment) instead of the specific DSM-IV criteria for
autism is used.
Twin Studies
In the first twin study of autism (Folstein & Rutter, 1977),
the concordance rate in monozygotic (MZ) pairs (36%) was
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significantly greater than that found in dizygotic (DZ) pairs
(0%). If the phenotype was expanded to include a cognitive
or a language disorder, the concordance rates were 82 and
10%, respectively. Two subsequent studies found an MZ/DZ
concordance rate of 91–0% (Steffenburg et al., 1989) or
60–5% utilizing the specific phenotype, and 90% vs. 10%
using the broader phenotype which included social or cog-
nitive deficits (Bailey et al., 1995). Across twin studies of
autism, the difference between MZ and DZ concordance
rates is sizable, averaging roughly 10:1 (Pennington, 2009).
This rate is greater than that for other psychiatric disor-
ders such as depression, bipolar disorder, and schizophrenia
(between 2:1 and 4:1), indicating a high heritability for
autism (Pennington, 2009). On the other hand, there was
great variability in IQ and clinical behaviors in the 16 MZ
pairs concordant for autism in the (Bailey et al., 1995)
study. In other words, there was no more similarity for these
traits within MZ pairs than that between individuals picked
at random from different MZ pairs who also had autism.
As interpreted by Pennington (2009), this finding suggests
that although autism is heritable, the genes may not dictate
the exact phenotype. Nonadditive interaction among genes
(epistasis) and nonshared environmental influences likely
contribute to these differences in phenotypes. Further, the
large disparity between the MZ and the DZ concordance
rates has been attributed to epistasis (Pennington, 2009).
Alternatively, rare gene variants causing a common disorder
(autism), as described below, could contribute to this large
MZ/DZ discordance.
Familiarity
Individuals with autism rarely marry and have children
so that vertical transmission of the diagnosis from parent
to child is rarely observed (Pennington, 2009). However,
genetic transmission is still possible as parents can transmit
genetic risk factors without having the diagnosis themselves.
Family studies (cited in Geschwind & Konopka, 2009;
Pennington, 2009) suggest that the risk of autism is 20–60%
higher in siblings compared to the incidence of autism in the
general population, and to that of other psychiatric disorders.
Several studies have shown that a broad autism phenotype
is transmitted in families of individuals with autism (Piven,
1999; Rutter, 2000). For example, first-degree relatives of
individuals with autism were shown to be shy, aloof, and
have problematic pragmatic language (Rutter, 2000). This
pattern is consistent with the segregation of sub-threshold
traits within these families (Abrahams & Geschwind,
2008).
Gender Differences
Finally, autism affects more boys than girls (4:1), a finding
which has remained constant since Kanner’s first description
of autism in 1945, and despite the increasing incidence of this
diagnosis. The predominantly male ratio has been attributed
to an abnormality on the X chromosome (discussed below),
or to sex linkage or genomic imprinting (Lintas & Persico,
2009; Marco & Skuse, 2006). Sex linkage involves a gene on
the X chromosome transmitted from the mother to the son.
As the son has only one X chromosome, this gene would
be expressed. Since the mother’s daughter has two copies of
the X chromosome – one from her father and one from her
mother – the daughter likely would not express the abnormal
phenotype. The most well-known example of a sex-linked
disorder is hemophilia, which is on the X chromosome.
Genomic imprinting, on the other hand, is an epigenetic
phenomenon wherein chemical modification of DNA that
does not alter the basic DNA sequence or modification of
the DNA-associated histone proteins determines whether the
maternal or the paternal copy of a specific gene is expressed.
Genomic imprinting has been determined for Prader Willi
and Angelman’s syndrome.
Finally, increased risk for autism has been identified in
the offspring of older fathers (Reichenberg et al., 2006).
Therefore, the gender and age of the parent may confer risk
for offspring with autism.
Genetic Models of Autism
The conclusion drawn from indirect evidence is that autism is
the most heritable and familial neurodevelopmental disorder
(Pennington, 2009). With rare exceptions, however, autism
does not appear to be the action of a single gene inherited
in a strictly Mendelian pattern (autosomal dominant, reces-
sive, or X-linked; Gupta & State, 2007; O’Roak & State,
2008). Rather, there are reports of multiple, distinctly rare
changes in the genetic code in small subsets of individuals
that cause or contribute to autism. There may be multiple
gene variants – “a conspiracy of multiple genes” (Gupta &
State, 2007) – that converge leading to a given phenotype.
Despite the indirect evidence for heritability and recent
genetic technological advances, a genetic cause can be
attributed to only 10–20% of all cases (reviewed in
Abrahams & Geschwind, 2008), with a recent report sug-
gesting a genetic cause can be uncovered in up to 40%
of cases (Schaefer & Lutz, 2006). Further, Abraham and
Geschwind (2008) state that no single genetic cause accounts
for more than 1–2% of cases – similar to what is seen in men-
tal retardation, another condition without a single genetic
cause. While numerous studies identifying candidate genes
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or makers have been reported, very few studies have been
replicated (Losh et al., 2008). Reasons to explain why can-
didates have not been agreed upon include the initial lack of
uniform diagnostic criteria (strict vs. broad definition), lim-
ited power, varying methodology (Losh et al., 2008), and
neglect of epigenetic factors modeling the disorder (Lahiri,
Maloney, & Zawia, 2009). Further, as with other conditions
with a strong heritable component, it appears that different
genes may contribute to distinct components of the condition
which gives rise to the full disorder through concerted actions
(Losh et al., 2008; Pickles et al., 1995). Consequently, it has
been said that linkage technology has not “found the autism
gene,” but rather it demonstrated that more powerful tech-
nology is necessary to explain the multiple genes associated
with autism (Abrahams & Geschwind, 2008). No one knows
just how heterogeneous the syndrome is likely to be, that is,
how many genes or regions of DNA (loci) may contribute
either within a single individual or among the entire group of
affected individuals. Some of the chromosomal regions and
genes that have been associated with autism are summarized
in Table 6.1 and will be addressed herein.
In addition, it is important to distinguish between locus
heterogeneity, which refers to a variation at many different
genes or loci resulting in a similar phenotype, and allelic het-
erogeneity, which refers to different variations or mutations
at the same locus leading to an identical or overlapping clin-
ical picture. Accumulating evidence suggest that both play a
role in autism (O’Roak & State, 2008).
Recently, a rare-variant common disease model has been
introduced (O’Roak & State, 2008). In this model, rare
genes explain the common disease of autism. This makes
sense in the Darwinian tradition that a deleterious change
Table 6.1 The polygenetics of autism, selected chromosomal regions, and genes
Chromosome
and locationa
Specific gene
(if applicable)
Gene name
(if applicable)
Normal protein function
(if applicable)
Autism-associated
endophenotypes
(if applicable)
References
2p16.3 NRXN1 Neurexin 1 Cell adhesion, receptor,
nervous system
Lintas and Persico
(2009), Etherton
et al. (2009);
Szatmari et al.
(2007)
2q IMGSAC (1998),
(2001b)
2q37 Costa de Silva
(2008); Schaefer and
Mendelsohn (2008)
5p15 Weiss et al., 2009
5p15.2 SEMA5A Sema domain, seven
thrombospondin repeats
(type 1 and type 1-like),
transmembrane domain
(TM), and short
cytoplasmic domain
(semaphorin) 5A
Involved in axonal
guidance during neural
development
Weiss et al. (2009)
6q27 Weiss et al. (2009)
7q Specific language
impairment
Losh et al. (2008)
7q21-22 IMGSAC (1998),
(2001a)
7q22 RELN Reelin Controls cell–cell
interactions critical for
cell positioning and
neuronal migration
during brain
development
Ashley et al. (2007);
Persico et al. (2002);
Zhang et al. (2002)
7q31 FOXP2 Forkhead box P2 Development of speech
and language regions of
the brain during
embryogenesis
Specific language
impairment
Konopka et al.
(2009); Lai et al.
(2001); O’Brien
et al. (2003)
7q31 Vincent et al. (2002)
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Table 6.1 (continued)
Chromosome
and locationa
Specific gene
(if applicable)
Gene name
(if applicable)
Normal protein function
(if applicable)
Autism-associated
endophenotypes
(if applicable)
References
7q31.1-31.3 ST7 Suppression of
tumorigenicity 7
Function not determined Vincent et al., 2002
7q31.2 WNT2 Wingless-type MMTV
integration site family
member 2
Implicated in
oncogenesis and in
several developmental
processes
Wassink et al. (2004)
Lai et al. (2001)
7q32-36 IMGSAC (1998);
CLSA (1999)
7q35-36 CNTNAP2 Contactin-associated
protein-like 2
Cell adhesion, local
axonal differentiation
Autism language
phenotype
Strauss et al. (2006),
Jackman et al.
(2009), Alarcon
et al. (2008)
9q34 TSC1 Tuberous sclerosis 1 Growth inhibitory
protein
Au et al. (2004);
Fryer et al. (1987)
10q23.3 PTEN Phosphatase and tensin
homolog
Tumor suppressor,
negatively regulates
AKT/PKB signaling
Macrocephaly Kwon et al. (2006);
Butler et al. (2005),
Herman et al.
(2007a)
11q12-p13 Szatmari et al.
(2007)
11q13 NRXN2 Neurexin 2 Cell adhesion, receptor,
nervous system
Lintas and Persico
(2009)
13q21 Specific language
impairment
Bartlett et al. (2002),
(2004)
14q31 NRXN3 Neurexin 3 Cell adhesion, receptor,
nervous system
Feng et al. (2006)
15q11-13 Mental retardation,
motor impairment,
seizure, impairment
in communication,
restrictive and
repetitive behavior
Cook et al. (1997);
Schroer et al. (1998);
Shao et al. (2003)
16p13.3 TSC2 Tuberous sclerosis 2 Tumor suppressor,
stimulates specific
GTPases
Au et al. (2004)
16q24 Specific language
impairment
SLI Consortium
(2002), (2004)
17p11 Costa e Silva (2008);
Schaefer and
Mendelsohn (2008)
17q11-17 Cantor et al. (2005)
17q11.1-q12 SLC6A4 Solute carrier family 6
(neurotransmitter
transporter, serotonin),
member 4
Transports serotonin
into presynaptic neurons
Losh et al. (2008)
18q21.2-22.3 Mahr et al. (1996)
19q13 Specific language
impairment
SLI Consortium
(2002), (2004)
20p13 Weiss et al. (2009)
21q21.2-21.3 APP Amyloid beta (A4)
precursor protein
Neurite outgrowth, cell
adhesion
Self-injurious and
aggressive behavior
Bailey et al. (2008);
Sokol et al. (2006)
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Table 6.1 (continued)
Chromosome
and locationa
Specific gene
(if applicable)
Gene name
(if applicable)
Normal protein function
(if applicable)
Autism-associated
endophenotypes
(if applicable)
References
22q11 Costa e Silva (2008);
Schaefer and
Mendelsohn (2008);
Sykes and Lamb
(2007)
22q13 Costa e Silva (2008);
Schaefer and
Mendelsohn (2008);
Sykes and Lamb
(2007)
22q13.3 SHANK3 SH3 and multiple
ankyrin repeat
domains 3
Connects
neurotransmitter
receptors, ion channels,
and other membrane
proteins to the actin
cytoskeleton and G
protein-coupled
signaling pathways, and
plays a role in synapse
formation and dendritic
spine maturation
Durand et al. (2007);
Moessner et al.
(2007)
Xp Schaefer and
Mendelsohn (2008)
Xq13.1 NLGN3 Neuroligin 3 Formation and
remodeling of central
nervous system
synapses
Jamain et al. (2003)
Xq22.31-32 NLGN4X Neuroligin 4, X-linked Formation and
remodeling of central
nervous system
synapses
Jamain et al. (2003),
Laumonnier et al.
(2004);
Lawson-Yuen et al.
(2008)
Xq27.3 FMR1 Fragile X mental
retardation 1
mRNA translation
regulation
Gaze avoidance,
stereotypic movements,
echolalia, ritualistic
behaviors
Einfeld et al. (1989);
Maes et al. (1993)
Xq28 MECP2 Methyl-CpG-binding
protein 2
Binds to methyl-CpG in
methylation regulation
of gene expression
Mental retardation,
female only
Lintas and Persico
(2009)
XY mosaicism Costa e Silva (2008);
Sykes and Lamb
(2007); Schafer and
Mendelsohn (2008)
XYY Costa e Silva (2008);
Schaefer and
Mendelsohn (2008)
aChromosome location, gene symbol, gene name, and protein function are from the NCBI Entrez gene database (http://www.ncbi.nlm.nih.gov/
gene/), accessed 1 January 2010.
in the human genome leads to reduced fitness and that
this would not be likely to propagate within a population.
Autism fits the rare gene-common disease model as it begins
early in life, impairs social interactions, and is associated
with mental retardation which impacts reproductive fitness
(O’Roak & State, 2008). The large difference seen between
monozygotic and dizygotic concordance rates is consistent
with de novo (rare gene) mutation. It appears that simplex
families demonstrate de novo mutations more frequently –
with one family member with autism (Sebat et al., 2007) –
whereas multiplex families demonstrate transmitted variants
(Bakkaloglu et al., 2008). The search for rare variants has
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led to the study of families that are genetically isolated,
with shared ancestry and prone to consanguinity (Morrow
et al., 2008; Strauss et al., 2006) to locate recessive alleles.
Finally, rare sequence variations have been detected, thanks
to improved technology such as CNV analysis. Indeed within
the last 5–10 years, 20 bona fide risk genes have been iden-
tified due to the improved technology developed after the
linkage method (Abrahams & Geschwind, 2008). Several of
these risk genes will be discussed in the following sections.
Genetic Research
Abrahams and Geschwind (2008) write that two views under-
lie genetic autism research. The first is that rare variants
involve an abnormality in a single molecule causing the clin-
ical pathology in autism. Mendelian inheritance (autosomal
dominant vs. recessive) takes this form. Technology com-
patible with this approach includes cytogenetics (including
karyotyping and FISH), gene association studies (analysis
of genes and protein system from less complex genetic
syndromes similar to autism such as Rett and fragile X
syndromes), linkage studies (including genome screens in
affected sibling pairs), microarray technology, and CNV
analysis. The second view involves the study of independent
hereditary endophenotypes representing the core features of
autism. An endophenotype is an operationally defined behav-
ioral feature such as age of first spoken word. Although there
is a general consensus regarding endophenotypes commonly
seen in autism, the behaviors may not be specific to autism,
as delay in language acquisition accompanies many develop-
mental disorders. Ideally, endophenotypes represent discreet
behaviors which do not overlap with other behaviors from
the autism core domains (i.e., language, socialization, and
rigid behavior). For example, poor eye contact, representing
a deficit with socialization, is construed as being independent
of repetitive behaviors, thought to represent the rigid behav-
ior domain. Genetic study of these discreet endophenotypes,
largely undertaken via linkage studies, narrows the scope of
analysis (Losh et al., 2008; O’Roak & State, 2008).
Cytogenetics: Rare Mutations
Reports of chromosomal abnormalities detected by kary-
otyping first demonstrated that rare variants may contribute
to autism (Vorstman et al., 2006). Estimates of chromoso-
mal abnormalities in autism range from 6 to 40% (Abrahams
& Geschwind, 2008; Marshall et al., 2008; Pennington,
2009; Schaefer & Lutz, 2006) so that genetic workup
is now being recommended for all children diagnosed
with autism (Pennington, 2009; Schaefer & Mendelsohn,
2008).
Chromosome 15q11-13
Chromosomal studies have produced a great interest in
chromosome 15q11-13, the site of the most frequent chro-
mosomal anomaly seen in autism (reviewed in Veenstra-
VanderWeele & Cook, 2004). The maternally derived dupli-
cation of this region involves an imprinting mechanism.
Maternal interstitial duplication or supernumerary inverted
duplication of 15q11-13 is seen in 1–3% of patients (Cook
et al., 1990; Schroer et al., 1998). Clinical features of chro-
mosomal derangement in this region include mental retarda-
tion, motor impairment, seizure disorder, and impairment in
communication, in some but not all with autism or attention-
deficit hyperactivity disorder (ADHD; Cook et al., 1997;
Schroer et al., 1998).
The duplication of 15q11-13 seen in some cases of autism
is the opposite of deletions from the same region seen
in Angelman’s syndrome (if inherited from the mother)
or Prader Willi syndrome (if inherited from the father).
Angelman’s syndrome, known as the “happy puppet” phe-
notype, involves mental retardation, epilepsy, ataxia, lack of
speech, predominant laughing and smiling, and a high rate
of autism. Prader Willi syndrome associated with mental
retardation and hyperphagia is only occasionally associated
with autism. Presently, there is ongoing research regarding
how duplications and deletions in this gene region lead to
an increased risk of autism (Veenstra-VanderWeele & Cook,
2004). This region, however, has not been identified as one
of interest in whole genome searches, perhaps due to its
rarity (Pennington, 2009). Still, FISH analysis of chromo-
some 15q11-13 is often performed in evaluation of children
with autism. Recently, FISH is being replaced by CGH due
to improved detection of abnormality within the 15q11-13
region.
Fragile X Syndrome
Cytogenetic approaches provided the first evidence for an
autism gene 40 years ago when Lubs (1969) identified an
abnormal or “fragile” site on the long arm of chromosome X
in four males with mental retardation, leading to the recogni-
tion of fragile X syndrome (FXS). This syndrome, associated
with mental retardation and autistic features, is more severely
expressed in males. FXS is caused by a deficiency of the
fragile X mental retardation protein (FMRP), resulting from
little or none of the disease gene fragile X mental retardation
1 (FMR1) mRNA. The FMR1 gene mutation consisting of
expanded CGG repeats of > 200 at chromosome site Xq27.3
is considered the origin of FXS. Autism, using the broad
definition, has been reported in up to 30% of males with
FXS, and FXS can be found in as many as 7–8% of indi-
viduals with autism (Muhle, Trentacoste, & Rapin, 2004).
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Later studies, using DNA measures of the fragile X mutation
rather than cytogenetics and strict autism criteria, have found
a smaller association between FXS and autism (Pennington,
2009). Two investigations, however, which studied carefully
controlled groups of FXS-negative and FXS-positive males
matched on intelligence, found higher rates of the follow-
ing autistic symptoms in FXS males: gaze avoidance and
hand flapping (Einfeld, Molony, & Hall, 1989) and stereo-
typic movements (including hand flapping, rocking, and
hitting, scratching, or rubbing their own bodies), echolalia,
gaze avoidance, and ritualistic behaviors (Maes, Fryns, Van
Walleghem, & Van den Berghe, 1993). Studies of endophe-
notype behaviors rather than the strict autism criteria are
more likely to uncover robust similarities between FXS and
autism.
Exploring similarities between rare sub-groups of patients
with a known disorder and those with a more common dis-
order (autism) provides a window into the shared biology
between the disorders. FMRP has been shown to interact
with multiple transcripts in repressing metabotropic gluta-
mate receptor-5 (mGluR5) signaling activity which regulates
long-term depression (LTD) associated with synaptic elim-
ination. Without FMRP acting as a “brake,” mGluR–LTD
is enhanced (Bear, Huber, & Warren, 2004). This favors an
anabolic state which could contribute to the key features of
FXS such as epilepsy, cognitive impairment, loss of motor
coordination, and increased density of thin, long, dendritic
spines in neurons (Bear, 2005). These observations have
invited drug trials of glutamate receptor antagonists to reduce
the expression of mGluR5 (Dolen et al., 2007) in individuals
with FXS and in individuals with autism.
Investigation of Candidate Genes Contributing
to Biochemical Pathways
Other genes contributing to medical conditions such as
Alzheimer’s disease are under investigation to determine if
they, too, share biology with autism and FXS. The discovery
of fragile X ataxia syndrome (FXTAS) provides a prece-
dent to study the relationship of developmental conditions
across the life span within and between families. FXTAS
is an adult-onset ataxia/dementia syndrome found in older
family members of individuals with FXS (Hagerman, 2002;
Hagerman et al., 2001). In contrast to what is found in FXS,
FXTAS occurs with a rise in FMR1 mRNA level (Hagerman,
2006), fewer than 200 repeats (Basehore & Friez, 2009), and
hypomethylation (Berry-Kravis, Potanas, Weinberg, Zhou, &
Goetz, 2005) in the FMR1 CGG section on the X chromo-
some. This association of two clinically divergent disorders,
regulated by the same gene produced in different doses, sets
the stage for the investigation of the shared biology between
autism, FXS, and other genes related to Alzheimer’s disease
such as amyloid precursor protein (APP).
Amyloid Precursor Protein
APP, which is encoded by a gene on chromosome 21, is
a large (695–770 amino acid) glycoprotein produced in
several central nervous system (CNS) cell types including
microglia, astrocytes, oligodendrocytes, and neurons. After
protein processing, mature APP is axonally transported and
can be released from axon terminals in response to electri-
cal activity. APP is believed to play an important role in
neuronal maturation and in synaptogenesis as reviewed by
Lahiri, Farlow, Greig, Giacobini, and Schneider (2003). APP
is of great interest because processing products of APP can
include the insoluble 40–42-amino acid amyloid β-peptide
(Aβ-40 and Aβ-42, respectively), the principal component
of the cerebral plaques associated with memory and cog-
nitive decline in Alzheimer’s disease (Alley et al., 2010).
Recent research linking APP to autism illustrates how associ-
ation studies enable the generation of new hypotheses about
the biology of autism and ultimately advance our under-
standing of this disorder. Recently, we found evidence to
support an association between autism and one of the APP
pathways established for Alzheimer’s disease. In contrast to
the upregulation of the amyloidogenic pathway as seen in
Alzheimer’s disease, we found evidence that there may be
an upregulation of the nonamyloidogenic (α-secretase amy-
loid precursor protein, sAPPα) pathway in a small sample
of children with severe autism associated with self-injurious
and aggressive behavior. That is, children with severe autism
expressed total sAPP (representing the combined amyloido-
genic and nonamyloidogenic pathways) at two or more times
the levels of children without autism and up to four times
the levels of children with mild autism (Sokol et al., 2006).
Overall, there was a trend toward higher sAPPα within the
children with autism. One of the severely autistic children
in this study had FXS. High levels of sAPPα have also
been found in a sample of children with autism from an
independent laboratory (Bailey et al., 2008). High levels of
sAPPα imply an increased α-secretase pathway in autism
(anabolic), opposite to what is seen in Alzheimer’s disease.
This would be consistent with the brain overgrowth hypoth-
esis attributed to autism, in contrast to the brain atrophy
seen with the deposition of amyloid plaque in Alzheimer’s
disease. Coincidentally, via animal studies, Westmark and
Malter (2007) concluded that FMRP binds to and regulates
translation of APP mRNA through mGLuR5, providing a
potential link between neuronal proteins associated with AD
and FXS. By way of mGluR5, FMRP provides the “brake,”
which if unchecked in conditions such as FXS would favor
high levels of APP. Further, high levels of APP have been
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found in another study of FMR1 knockout mice (D’Agata
et al., 2002). These findings have led to enticing speculation
that the APP gene may influence several neurodevelopmental
disorders across the life span.
Chromosome 7q
Both chromosomal inversions and translocations have been
reported near 7q31 in boys with autism. One of these
translocation breakpoints identified the deranged gene as
RAY1/ST7 (FAM4A1), a putative tumor suppressor gene
(Vincent et al., 2002), and work in this region is ongoing.
Mutations leading to amino acid changes have been found
on the WNT2 gene on 7q31 in two families with autism,
and one affected parent transmitting the mutation to two
affected children (Li et al., 2004; Wassink, Brzustowicz,
Bartlett, & Szatmari, 2004). The FOXP2 gene on 7q31
was found to be disrupted in one family with an autoso-
mal dominant form of specific language impairment (SLI)
(Lai, Fisher, Hurst, Vargha-Khadem, & Monaco, 2001),
and this was replicated in a larger study of SLI (O’Brien,
Zhang, Nishimura, Tomblin, & Murray, 2003), although ini-
tial studies failed to associate this with autism (Newbury
et al., 2002; Wassink et al., 2001). Recently, FOXP2 dif-
ferences in gene expression were found between chimp and
human cell cultures (Konopka et al., 2009). Compared to
chimps, in human culture, the FOXP2 gene affected tran-
scription upregulation in 61 genes and downregulation in
55 genes. Further, the FOXP2 gene was shown to regu-
late downstream effects involving cerebellar motor function,
craniofacial formation, and cartilage and connective tissue
formation required for expressive language. As discussed in
section “Endophenotype,” there is a suspected association
between the chromosome 7q region and speech abnormality
seen in autism.
The RELN gene maps to chromosome 7q22. This gene
encodes a protein that controls intercellular interactions
involved in neuronal migration and positioning in brain
development. A large polymorphic trinucleotide repeat in the
5′-YTR of the RELN gene has been implicated in autism
in several studies (Ashley-Koch et al., 2007; Persico et al.,
2002; Zhang et al., 2002). Further support for this candidate
gene comes from the RELN mouse model which carries a
large deletion in RELN and shows atypical cortical orga-
nization similar to cytoarchitectural pathological anomalies
reported in the brains of individuals with autism (Bailey
et al., 2008).
Phosphatase and Tensin Homolog Gene (PTEN)
PTEN is a tumor suppressor gene located on chromosome
10q23. This gene influences the cell–cell arrest cycle and
apoptosis or programmed cell death (Lintas & Persico,
2009). PTEN inactivation causes excessive growth of den-
drites and axons, with an increased number of synapses
(Kwon et al., 2006). Mutations in PTEN cause Cowden’s
syndrome (macrocephaly, hamartomas, and autism). This
gene has been of interest to autism researchers as macro-
cephaly has been considered to be one of the “most widely
replicated biological findings in autism” affecting up to 20%
of all children with the condition (McCaffery & Deutsch,
2005). Butler et al. (2005) examined the PTEN gene in 18
individuals with autism and macrocephaly. They discovered
three with PTEN missense mutations. Others have found
PTEN mutations in macrocephalic patients with autism
(Herman et al., 2007a, 2007b).
Other Cytogenetic Regions
Cytogenic abnormalities have included deletions and dupli-
cations involving 2q37, 22 q13, 22q11, 17p11, 16p11.2,18q,
Xp, and sex chromosome aneuploidies (47, XYY and 45,
X/46, and XY mosaicism) (Costa e Silva, 2008; Mendelsohn
& Schaefer, 2008; Schaefer & Mendelsohn, 2008; Sykes &
Lamb, 2007). These genetic findings have generated interest
in testing the association of a number of candidate genes in
these regions via linkage and animal studies.
Autism and Synapse Formation (Synaptogenesis)
Overview
Accumulating evidence points to the involvement of three
genes (neuroligin, SHANK3, and neurexin) in the synapse
formation of glutamate neurons. Glutamate is an excitatory
neurotransmitter and aberrant glutamate function has long
been suspected to contribute to autism. Neuroligins induce
presynaptic differentiation in glutamate axons. SHANK3
encodes for a postsynaptic scaffolding protein which reg-
ulates the structural organization of dendritic spines in
neurons. Consequently, SHANK3 is a binding partner of
neuroligins. Neurexin induces glutamate postsynaptic dif-
ferentiation in contacting dendrites. Altogether, these genes
appear to contribute to glutamatergic synapse formation.
Neuroligin Genes (NLGN3 and NLGN4)
Neuronal cell adhesion is important in the develop-
ment of the nervous system, contributing to axonal guid-
ance, synaptic formation and plasticity, and neuronal–
glial interactions (Glessner et al., 2009; Lien, Klezovitch,
& Vasioukhin, 2006). Derangement in cell adhesion
could contribute to migrational abnormalities including
brain overgrowth. Neuroligins are cell-adhesion molecules
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localized postsynaptically at both glutamatergic (NLGN1,
NLGN3, NLGN4, NLGN4Y) and γ-aminobutyric acidergic
(NLGN2) synapses (Lintas & Persico, 2009). Neuroligins
trigger the formation of functional presynaptic structures in
contacting axons. As mentioned above, they interact with
postsynaptic scaffolding proteins such as SHANK3 (see
below). The NLGN3 and NLGN4 genes are located at chro-
mosomes Xq13 and Xq22, 33, respectively, and mutations
here have been associated with autism Jamain et al. (2003).
Extensive genetic screens conducted by several research
groups have confirmed the low frequency of neuroligin muta-
tions among individuals with autism (Lintas & Persico,
2009). For example, Jamain et al. (2003) found a frameshift
mutation in NLGN4 and a missense mutation in NLGN3 in
two unrelated Swedish families, inherited from unaffected
mothers. Laumonnier et al. (2004) reported a frameshift
mutation in NLGN4 in 13 affected male members of a sin-
gle pedigree. Lawson-Yuen, Saldivar, Sommer, and Picker
(2008) found a deletion of exons 4–6 of NLGN4 in a boy
with autism and in his brother with Tourette syndrome whose
mother showed psychiatric problems and also carried the
mutation. Neuroligin mutation carriers, however, display a
variety of syndromes, such as X-linked mental retardation
without autism (Laumonnier et al., 2004), Asperger’s syn-
drome, autistic disorder of variable severity, and PDD-NOS
(Yan et al., 2005). The symptoms may be slow, or abrupt
and associated with regression. Despite intensive investiga-
tion, the low frequency of neuroligin mutations and the lack
of similar phenotypes have led to the recommendation that
neuroligins should not be included in widespread screens
for individuals with nonsyndromic autism (Lintas & Persico,
2009).
SH3Multiple Ankyrin Repeat Domains 3 Gene
(SHANK3)
The SHANK3 gene is located on chromosome 22q13.3 which
encodes for a scaffolding protein found in the postsynaptic
density complex of excitatory synapses binding to neu-
roligins. Recently, two studies have reported a correlation
between mutations affecting SHANK3 and an autism phe-
notype characterized by severe verbal and social deficits
(Durand et al., 2007; Moessner et al., 2007). Of the
seven patients reported with the SHANK3 gene mutations,
five were deletions, one was a missense, and another a
frameshift mutation. In addition, rare SHANK3 variations
were present in the autism group, but not in the con-
trol group. These variations were inherited from healthy
parents and they were present in unaffected siblings, per-
haps demonstrating incomplete penetrance. Another inter-
esting observation is that in both studies (Durand et al.,
2007; Moessner et al., 2007), the SHANK3 deletion was
inherited via a paternal balanced translocation. Further,
in both studies, siblings of the probands with SHANK3
abnormalities had partial 22q13 trisomy that resulted in
attention-deficit hyperactivity disorder (Moessner et al.,
2007) and Asperger’s syndrome with early language devel-
opment (Durand et al., 2007). Like neuroligins, SHANK3
mutations are very rare. However, because of the robust
genotype–phenotype correlation reported in two studies
(Durand et al., 2007; Moessner et al., 2007), it has been
recommended that children with severe language and social
impairment obtain SHANK3 mutation screening (Lintas &
Persico, 2009).
Neurexin Genes
Presynaptic neurexins influence postsynaptic differentiation
in contacting dendrites by interactions with postsynaptic
neuroligins. Three neurexin genes (NRXN1, NRXN2, and
NRXN3) are located on chromosome loci 2q32, 11q13, and
14q24.3-q31.1, respectively. Again, neurexin mutations are
very rare. For example, two missense mutations were present
in 4 of 264 (1.5%) individuals with autism compared to
none in 729 controls (Feng et al., 2006). However, in this
study, missense mutations also occurred in first-degree rel-
atives who displayed heterogeneous phenotypes such as
hyperactivity, depression, and learning problems. Incomplete
penetrance may explain these findings, or autism may be
caused by neurexin acting synergistically with other sus-
ceptibility genes. Neurexin-1α is being intensely studied in
mice as deletion in this molecule resulted in increased repet-
itive behavior, whereas social behavior was relatively intact
(Etherton, Blaiss, Powell, & Sudhof, 2009). This implies
an animal model for a discreet feature of autistic behavior
(endotype), as discussed below.
Contactin-associated protein-like 2 (CNTNAP2) is a
member of the neurexin superfamily which involves a reces-
sive frameshift mutation on chromosome 7q35. It is one
of the largest genes of the human genome and encodes
CASPR2, a transmembrane scaffolding protein. CNTNAP2
has been associated with cortical dysplasia–focal epilepsy
in an Old Order Amish community (Strauss et al., 2006).
Autism was present in up to 67% of these individuals. We
recently reported CNTNAP2 in an Amish girl with epilepsy
and autism who also showed hepatosplenomegaly (Jackman,
Horn, Molleston, & Sokol, 2009). CNTNAP2 has been asso-
ciated with an autism language phenotype in large studies
of non-Amish individuals (Alarcon et al., 2008). Further,
stage two of this investigation showed that CNTNAP2 was
expressed in the language centers (frontal and anterior tem-
poral lobes) of fetal brain (Alarcon et al., 2008). It has been
recommended that Amish children presenting with autism
should be tested for CNTNAP2 gene mutation (Strauss,
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personal communication). This work again supports a lan-
guage function associated with chromosome 7.
TheMethyl-CpG-Binding Protein 2 Gene
Methyl-CpG-binding protein 2 (MeCP2) works as a tran-
scriptional repressor within gene-promoting regions involved
in chromatin repression. This gene is located on chromo-
some Xq28 and shows mutation in 80% of females with
Rett syndrome (pervasive developmental disorder, acquired
microcephaly, epilepsy, and loss of hand function). This
gene has been studied in children with autism, and MeCP2
mutations are considered to be rare (0.8–1.3%) in females
with autism. Interestingly, autism and Rett syndrome share
some similarities at the phenotypic and pathogenic levels,
and both disorders were proposed to result from disrup-
tion of postnatal or experience-dependent synaptic plasticity
(Zoghbi, 2003). Among the Rett mutations reported are a
frameshift mutation, a nonsense mutation, and additional
introns (Lintas & Persico, 2009). Schaefer and Mendelsohn
(2008) observe that MeCP2 has not been associated with
idiopathic autism in males so that this gene test is recom-
mended only for females with autism.
Linkage Studies
Linkage studies involve determining whether the transmis-
sion of a chromosomal segment from one generation to
another coincides with the presence of the phenotype of
interest (Gupta & State, 2007). Linkage can be utilized in
Mendelian inherited conditions and can also be used to study
complex conditions such as in autism when Mendelian inher-
itance is unlikely, and there is no hypotheses regarding the
specific nature of transmission.
Linkage studies can be grouped into two types – the
conventional study of a chromosomal region of interest
in affected sibling–pairs from multiplex families and the
more recent genome-wide linkage analysis in which every
chromosome is evaluated simultaneously. In the sib–pair
study method, siblings with autism are evaluated to deter-
mine whether they share any regions of the genome more
frequently than would be expected by chance.
Genomic wide association studies compare genetic risk
factors in the form of specific genetic markers in cases and
controls. These markers are distributed within the entire
genome rather than limited to specific gene regions such as
in the sib–pair method. This enables a more unbiased ascer-
tainment of regions of interest (Losh et al., 2008). Several
genome-wide scans of individuals with autism have been
reported and evidence in favor of linkage has been deter-
mined for the majority of chromosomes (Gupta & State,
2007). The trouble with these studies is that the evidence
has not reached statistical significance and there is lack of
replication for many of these findings. Statistical signifi-
cance is calculated by a logarithm of the odds (LOD) score.
This score represents the logarithm of the likelihood ratio of
observing the data under a model of linkage to observing the
data under a model of free recombination (no linkage). An
LOD score of 3.5 in a sib–pair analysis is considered to be
a significant linkage (Lander & Kruglyak, 1995). Suggestive
linkage is an LOD score of 2.2, and a highly significant LOD
score is 5.4. For replication studies, the replication thresh-
old is considered to be 1.4 (Lander & Kruglyak, 1995). By
chance, one would expect to see a suggestive linkage peak
once every genome scan or a significant peak once every 20
scans (Gupta & State, 2007).
Most linkage studies have identified linkage regions
reaching the level of suggestive linkage at best (Freitag,
2007). Despite large increases in the size of patient cohorts,
linkage signals have not increased significantly with sam-
ple size (Abrahams & Geschwind, 2008). Only three loci
(2q, 7q, and 17q11-17) have been replicated for nonsyn-
dromic autism and are considered to have genome-wide
significance. Genomic-wide screens have engendered great
interest in chromosome 7q with distinctive peaks involv-
ing two distinct regions: 7q21-22 and 7q32-36 (International
Molecular Genetic Study of Autism Consortium-IMGSAC,
1998; Collaborative Linkage Study of Autism, 2001). As
chromosome 7q has been discussed in section “Cytogenetics:
Rare Mutations,” chromosome 2 and then 17q11 will follow
the description of how linkage studies led to the discovery
of the gene loci for a syndromic form of autism: tuberous
sclerosis complex (TSC). The sibling–pair from multiplex
family design has been used to study autism within many
genetic loci, including those involved in TSC; the genome-
wide linkage analysis has detected linkage on chromosomes
7q, 2q, 17q11, and novel loci.
Tuberous Sclerosis Complex
Tuberous sclerosis complex (TSC) is a neurodevelopmen-
tal disorder characterized by cognitive delay, epilepsy, and
neurocutaneous growths including hamartomas (i.e., tubers)
within the central nervous system and other organs. Up
to 60% of individuals with TSC have autism. The first
suspicion of a chromosomal abnormality associated with
TSC originated from a linkage study of 26 protein mark-
ers within 19 multigenerational families affected with TSC
(Fryer et al., 1987). In eight of the families, ABO blood
group gene mapped to chromosome 9q34.3. Many groups
corroborated these results using larger numbers of families
(Au, Williams, Gambello, & Northrup, 2004). These linkage
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studies established the TSC1 gene, later discovered to encode
hamartin, a growth suppressor protein.
Another TSC gene site was discovered via linkage stud-
ies on chromosome 16p13.3, known as TSC2. This gene
produces the tumor suppressor protein tuberin. Further evi-
dence showed that hamartin works together with tuberin
in several cell-signaling pathways including a growth
and translation regulatory pathway (P13K/PKB), a cell
adhesion/migration/protein transportation pathway [glyco-
gen synthase kinase 3 (GSK3)/β-catenin/focal adhesion
kinase/Ras-related homolog (Rho) pathway], and a cell
growth and proliferation pathway [mitogen-activated pro-
tein kinase (MAPK)]. The tuberin–hamartin complex affects
mTOR kinase activity (Au et al., 2004), promoting tumor
growth. This discovery has led to the study of rapamycin,
a drug used in organ transplant and cancer treatment, as a
therapy for suppressing growth of tumors in TSC (Kenerson,
Aicher, True, & Yeung, 2002).
Other growth-promoting genes such as PTEN have been
linked to the tuberin–hamartin gene complex as contributors
to the general overgrowth in TSC. As previously discussed,
PTEN is a gene of interest in autism.
Chromosome 2q
Buxbaum et al. (2007), together with the Seaver Autism
Research Center (SARS), reported a two-point dominant
LOD score of 2.25 on chromosome 2q in 35 affected sib-
ling pairs. In a second-stage screening which employed 60
families with autism probands, the strongest linkage was at
this same location. The IMGSAC study showed a strong link-
age to 7q as described above, but also found linkage to 2q
(IMGSAC, 1998), with a more recent study also providing
evidence for linkage to 2q (IMGSAC, 2001b).
Chromosome 17q
Early recognition of the need for large patient cohorts and
substantial genetic heterogeneity led to the establishment of
the autism genetic resource exchange (AGRE) composed of
over 500 families. AGRE is a publically available resource
of phenotypic data and biomaterials. Genomic scan linkage
analysis was performed on 109 autistic sibling pairs from 91
AGRE families together with analysis of those pairs from an
independent sample of 345 families from the same AGRE
cohort (Cantor et al., 2005). When families with autism
were stratified into only those with affected males, there
was significant linkage at 17q11-21 in both samples. The
LOD score for this replicated work was at genome-wide level
of significance (LOD score > 1.4). One positional candidate
gene close to this region is the serotonin transporter gene
(SLC6A4) which codes for a protein controlling the reuptake
of serotonin in the synapse. This was exciting as elevated
levels of serotonin have been determined in 25–30% of cases
of autism (Cook et al., 1990). Indeed, relationship between
the SLC6A4 site and a repeat polymorphic region in its pro-
moter region (5HTTLPR) recently has been independently
investigated (Losh et al., 2008). The chromosome 17q locus,
however, has not been uniformly observed in subsequent,
large-scale studies (Schellenberg et al., 2006) which may be
due to phenotypic heterogeneity.
Novel Loci for Autism
A very recent genome-wide linkage mapping study in a
sample of 1,031 multiplex autism families (Weiss, Arking,
Daly, & Chakravarti, 2009) identified significant linkage
on chromosome 20p13 and suggestive linkage on chromo-
some 6q27. In this study, no associations meeting criteria
for genome-wide significance were found, suggesting there
are not many common loci of moderate to large effect size.
However, replication data revealed a novel SNP locus on
chromosome 5p15. This region was adjacent to SEMA5A, a
member of the semaphoring axonal guidance protein family
which has been shown to be downregulated in transformed B
lymphocytes from autism samples (Weiss et al., 2009). The
authors further demonstrated lower SEMA5A gene expres-
sion in autism brain tissue. This finding is in keeping with the
suspected derangement in the migration of cortical neurons
during embryogenesis in autism.
Microarray Technology
Microarray technology is transforming the identification
of chromosome duplications and deletions (Gupta &
State, 2007). This new technology, known as high-density,
oligonucleotide-based array comparative genomic hybridiza-
tion (aCGH), is now available for widespread use. This
technique uses patient DNA and control DNA, each labeled
with a fluorescent tag (red or green). Equal amounts of DNA
from patient and control are hybridized to known regions
of the human genome pre-arrayed on a slide. If patient and
control have equal copy numbers at a given locus, the color
turns yellow, representing an equal measure of DNA. If the
patient has lost (deleted) a locus, only the control color is
visualized. If the patient has an extra copy at a locus (dupli-
cation), the patient color predominates. The aCGH probe
may be enriched for known genes or specific chromosomal
regions for known syndromes, or distributed evenly across
the whole genome. This new technique is now available at
all major medical centers and through Signature Genomic
Laboratories (www.signaturegenomics.com).
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Single-nucleotide polymorphism (SNP) analysis probes
thousands of SNPs and provides data about copy number and
genotype (Li & Andersson, 2009). The genotype can be used
to study uniparental disomy (UPI) seen in imprinting disor-
ders and consanguinity. This technique is better at focused
study of specific gene regions instead of the whole genome.
Additionally, SNP analysis uses pre-established laboratory
standards rather than intraexperimental controls. Both SNP
analysis and aCGH map produce copy number variation, and
it is common for labs to first perform aCGH and follow up
with SNP in specific regions of interest.
Today, CNV from several thousand nucleotides can be
identified, greatly improving upon the sensitivity of conven-
tional cytogenetics. Sebat et al. (2007) showed that CNVs
were present in 10% of affected individuals from single-
incidence autism families (i.e., sporadic cases), contrasting
with substantially lower rates observed in controls (1%) and
autism cases from multiplex families (3%). This has led to
the general expectation that de novo CNVs are more likely
to be found in sporadic (and as it turns out, dysmorphic)
cases. Jacquemont et al., 2006 reported CNV rearrangements
in 8 (27.5%) of 29 patients with syndromic autism (includ-
ing facial dysmorphism, limb or visceral malformations, and
growth abnormalities). There were no reoccurrence or over-
lap in these variants for the eight children. Chromosome
11q12-p13 and neurexins were implicated in a linkage study
using SNP–CNV in 1,181 families with at least two affected
individuals through the Autism Genome Project (Szatmari
et al., 2007).
Microarray technology, however, comes with the realiza-
tion that typically developing individuals have more struc-
tural variants than previously imagined (Sebat et al., 2007).
There is growing concern that CNV irregularities may not be
pathological and therefore not be a cause of autism (Tabor
& Cho, 2007). These authors note that using diagnostic
tools prematurely in a clinical context may be “unethical,
either because of over-treatment, under-treatment, unwar-
ranted labeling and stigmatization, or a false sense of secu-
rity.” Certainly, further studies on large cohorts of children
with the same deletion/duplication are necessary to enable
clinical application of this technology.
Endophenotypes
Due to the phenotypic heterogeneity of autism and the
lack of finding a specific gene, researchers have narrowed
the scope of analysis to more pure, operationally defined
behaviors/traits. Endophenotypes are behavioral, physiolog-
ical, and/or neuropsychological markers that are present in
both affected and unaffected individuals. Rather than search-
ing for “autism genes,” endophenotype investigations search
for smaller grouping of genes that contribute to discreet
phenotypes (Losh et al., 2008). This approach allows for
measurement of “dosage” of a trait and can be applied to
affected as well as unaffected individuals.
Specific Language Impairment
Specific language impairment (SLI) is defined as the fail-
ure of normal development of language without hearing loss,
mental retardation, or oral motor, neurological, or psychiatric
impairment. This affects approximately 7% of children enter-
ing school (Tomblin et al., 1997). Individuals with SLI per-
form poorly on phonologically based tasks and many go on to
develop dyslexia (Stothard, Snowling, Bishop, Chipchase, &
Kaplan, 1998). There appears to be neurostructural associa-
tion between SLI and autism (Herbert et al., 2002; 2004), and
there is an associated finding of language delay in relatives of
probands with autism (Wassink et al., 2004). Several inves-
tigations have found strong linkage of SLI to chromosome
13q21 (Bartlett et al., 2002; 2004) and to chromosomes 16q
and 19q (SLI Consortium, 2002, 2004). This finding is note-
worthy as it directly overlies the 16q locus linked to autism
(Wassink et al., 2004). A specific language marker, age of
first word, has shown significant linkage to chromosome 7
observed by five separate investigators (Losh et al., 2008).
The 7q region has been the subject of intense investigation, as
described above, and may be the loci associated with autism
language.
Restrictive and Repetitive Behavior
The restricted and repetitive behavior (RRB) endopheno-
type in children with autism is receiving attention (Morgan,
Wetherby, & Barber, 2008). RRB comprises one prong of
the autism clinical triad (language deficit, social deficit, and
RRB). Cuccaro et al. (2003) identified two factors underlying
RRB as measured by the Autism Diagnostic Interview-
Revised (ADI-R): repetitive sensory motor actions and resis-
tance to change. This is of interest as a genetic linkage signal
has been reported for resistance to change on chromosome 15
(Shao et al., 2003). It appears that the analysis of phenotypic
homogeneous subtypes may be a powerful tool for mapping
of candidate genes in complex traits such as autism.
Clinical Genetics Evaluation
The recent marked increase in the incidence and awareness
of autism has resulted in an increase in the number of chil-
dren sent for diagnostic evaluation. The general consensus
within the literature is that genetic consultation should be
conducted on all persons with the confirmed diagnosis of
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autism. While referral for genetic consult is often preferred,
often the primary practitioner, pediatrician, and/or pediatric
neurologist are in a position to conduct the initial evaluation.
Further, clinical geneticists may not be available, particu-
larly in underserved areas of the country, or a timely genetic
evaluation may not be possible due to lengthy waiting lists.
Therefore, the clinician taking care of a child with autism
may wish to initiate the genetic evaluation.
Recently, sequential guidelines for clinical genetics
evaluation in autism have been published by Schaefer,
Mendelsohn, and the Professional Practice and Guidelines
Committee (2008) (see Box 6.5). These evidence-based
guidelines have evolved from an original retrospective study
of patients referred for clinical genetics evaluation between
the years 2002 and 2004 at the University of Nebraska
Medical Center (Schaefer & Lutz, 2006). The guidelines
are dynamic rather than static and have been updated,
for example, as aCGH has become more available. The
stepwise approach was designed to balance cost with the
expected yield of the tests. Further, there is a pyramidal
effect so that “earlier tiers have a greater expected diag-
nostic yield, lower invasiveness of testing, better potential
of intervention, and easier overall practicality” (Schaefer
& Mendelsohn, 2008). Summarizing the diagnostic yields
expected for the following investigations (high-resolution
chromosome studies, 5%; aCGH – beyond that detected by
chromosome analysis – 10%; fragile X, 5%; MECP2, 5%
women only; PTEN, 3% if head circumference >2.5 SD;
other, 10%), it was predicted that utilization of these guide-
lines would lead to diagnosis in 40% of cases (Schaefer,
Mendelsohn, and the Professional Practice and Guidelines
Committee (2008). Finally, this stepwise approach has met
the approval of third-party payers and families (Schaefer &
Lutz, 2006).
Box 6.5 Template for the Clinical Genetic Diagnostic
Evaluation of Autism Spectrum Disorders
Pre-evaluation
Confirmation of diagnosis of autism by trained pro-
fessional using objective criteria and tools
Sensory screening (complete audiogram)
Electroencephalogram – if clinical suspicion of
seizures
Cognitive testing
Verify results of newborn screening
(High-resolution chromosomal analysis and fragile
X studies may be performed before referral)
First tier
Initial evaluation to identify known syndromes or
associated conditions
Examination with special attention to dysmorphic
features
Should include Wood’s lamp evaluation
If specific diagnosis is suspected, proceed with tar-
geted testing
Rubella titers – if clinical indicators present
“Standard” metabolic screening – if clinical indica-
tors present and if suspected condition was not
assessed by newborn screening
Urine mucopolysaccharides and organic acids
Serum lactate, amino acids, ammonia, and acylcar-
nitine profile
High-resolution chromosomal analysis – if not
already performed.
Second tier
Fibroblast karyotype if leukocyte karyotype is nor-
mal and clonal pigmentary abnormalities are
noted
Comparative genomic hybridization (chromosomal
microarray)
MECP2 gene testing (females only)
PTEN gene testing (if head circumference is 2.5 SD
greater than the mean)
Third tier
Brain magnetic resonance imaging
Serum and urine uric acid
If elevated, hypoxanthine–guanine phosphoribosyl-
transferase (HgPRT) and
Phosphoribosylpyrophosphate (PRPP) synthetase
superactivity testing
If low, purine/pyrimidine panel (uracil excretion,
xanthine, and hypoxanthine)
If severe language deficit, check for Shank3
mutation∗
Extracted from Shaefer, GB, Mendelsohn, NJ &
the Professional Practice and Guidelines Committee
(2008). Clinical genetics evaluation in identifying the
etiology of autism spectrum disorders. Genetics in
Medicine, 10, 301–305 and used with the authors’
permission.
∗Recommended by Sokol and Lahiri
Pre-evaluation
This initial step includes confirming the diagnosis of autism
using objective (DSM-IV) criteria and/or standardized objec-
tive measures such as those discussed in Chapter 15. An
audiogram is obtained to rule out hearing loss and an elec-
troencephalogram (EEG) is obtained if there is a clinical
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suspicion of seizures. Cognitive testing, when appropri-
ate, can determine mental retardation. Finally, verifying the
results of the newborn screen can help rule out rubella
and PKU.
Tier 1
Initial assessment involves a standard clinical genetic his-
tory and physical exam to identify known syndromes or
associated conditions. Included would be a Wood’s lamp
examination of the skin to help rule out neurocutaneous
conditions such as TSC. Also, for suspected diagnoses, stan-
dard metabolic screening is performed to check for urine
mucopolysaccharides and organic acids as well as serum lac-
tate, amino acid, ammonia, and acylcarnitine profile. If not
already performed, high-resolution chromosomal analysis
and DNA for fragile X is sent.
Tier 2
If the studies in the first tier are unrevealing, the second tier
checks for aCGH duplications and deletions. For patients
with pigmentary abnormalities on exam but with a normal
leukocyte karyotype, skin biopsy can be obtained to obtain
a fibroblast karyotype. For females, MECP2 gene testing is
obtained; for children with head circumference greater than
2.5 SD from the mean, PTEN gene testing is recommended.
Tier 3
Lower yield tests have been reserved for this level: brain
magnetic resonance imaging and serum and urine uric acid.
Further tests are outlined depending on the results (high or
low) of the uric acid tests. We would add here that if a child
has significant language impairment, a Shank3 mutation
should be ruled out.
Finally, new susceptibility loci that can contribute to
the autism phenotype are continually identified and cata-
logued in the Online Mendelian Inheritance in Man (OMIM)
database (http//www.ncbi.nlm.nih.gov/sites/entrez). Using
this search engine, a patient’s phenotype including dysmor-
phic features can be entered into the program to generate a
list of possible genetic diagnoses.
Counseling
Most clinical geneticists work with genetic counselors who
interpret the findings into recurrent risks for full siblings.
The tiered clinical genetics evaluation should identify two
groups of individuals: those with and those without an iden-
tifiable etiology for autism. For those without an identifiable
etiology, counseling should be provided according to multi-
factorial inheritance (Schaefer & Mendelsohn, 2008). That
is, 4% recurrence rate if the proband is a girl and 7% if the
proband is a boy. If a second child has autism, a reasonable
recurrence rate, based upon published reports, is 30%.
Acknowledgment Thanks to Bryan Maloney, M.S. for his help in
editing this manuscript.
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